GotoPER - Physicians' Education Resource
Back to Home
Video

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments

Create AccountAlready Registered? Login Here

Release Date

February 20, 2025

Expiration Date

March 28, 2025

Credits

1.0 CME, NCPD

Release Date: February 20, 2025

Expiration Date: March 27, 2025

Activity Overview

This educational activity is a rapid archive of the Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments presentation held on February 13, 2025.

Target Audience

This educational program is directed toward medical oncologists, APPs, nurses, pharmacists, researchers, and other healthcare professionals involved in the treatment of HR+/HER2- breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess the impact of testing modalities for identifying patients with high-risk early-stage HR+/HER2- breast cancer in determining therapy selection and need for adjuvant therapies
  • Assess the efficacy and safety profiles of current and emerging agents used in adjuvant endocrine regimens for patients with high-risk early-stage HR+/HER2- breast cancer who are suitable for intensified adjuvant endocrine therapies
  • Integrate recent evidence on biomarkers and clinical trials into personalized adjuvant treatment management for patients with early-stage HR+/HER2- breast cancer
  • Evaluate the impact of new clinical evidence for novel treatment classes on HR+/HER2- breast cancer treatment paradigms and their implications for clinical practice and adverse effect management
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Exact Sciences Corporation and Lilly.

You Also Might Like...

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast CancerFree CE/CME

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment ParadigmsFree CE/CME

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

3rd Annual Hawaii Cancer ConferenceLive Event

3rd Annual Hawaii Cancer Conference

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New DecisionsFree CE/CME

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Course

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments

Create Account